By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a clinical study for its SHR-2173 in primary membranous nephropathy (PMN).
Drug Mechanism
SHR-2173 is an in-house developed therapeutic biologic product designed to target abnormally activated immune cells. It exerts anti-inflammatory and immunosuppressive effects, aiming to reduce autoantibody levels and improve disease activity in patients with PMN.
Potential Impact
This novel therapy has the potential to offer a new treatment option for patients with PMN. Notably, there are currently no approved drugs or clinical-stage candidates with the same mechanism of action globally for PMN treatment, positioning SHR-2173 as a first-in-class investigational therapy.-Fineline Info & Tech